ResearchBarriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia
ResearchThe ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy
ResearchReduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients
ResearchThe OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma
ResearchSafety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome
ResearchDual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia
ResearchA case series of oral decitabine-cedazuridine with venetoclax for blastic plasmacytoid dendritic cell neoplasm
ResearchSynergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias
ResearchBLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia
ResearchCharacteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements
ResearchA Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
ResearchBexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trial
ResearchOutcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML